Literature DB >> 3789963

Hemodiafiltration treatment of deep hepatic coma by protein passing membrane: case report.

M Yoshiba, H Yamada, Y Yoshikawa, K Fujiwara, G Toda, H Oka, T Sanjo, Z Yamazaki, Y Idezuki, N Inoue.   

Abstract

Based on the assumption that middle molecules that induce hepatic coma occur in the plasma of patients with fulminant hepatic failure (FHF), the authors have developed a hemodiafiltration (HDF) method using a large-pore poly(methylmethacrylate) (PMMA) membrane that allows proteins to pass through. PMMA HDF resulted in complete recovery of deep coma and long-term survival in a patient with severe FHF. Although a large-scale controlled trial is needed, PMMA HDF is believed to be promising as a future artificial liver support.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3789963     DOI: 10.1111/j.1525-1594.1986.tb02590.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  9 in total

1.  Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment.

Authors:  M Yoshiba; K Sekiyama; F Sugata; H Okamoto; K Yamamoto; S Yotsumoto
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

Review 2.  Artificial and bioartificial liver support: a review of perfusion treatment for hepatic failure patients.

Authors:  Katsutoshi Naruse; Wei Tang; Masatoshi Makuuch
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

Review 3.  Artificial liver support: future aspects.

Authors:  Katsutoshi Naruse
Journal:  J Artif Organs       Date:  2005       Impact factor: 1.731

4.  Development and perspectives of perfusion treatment for liver failure.

Authors:  Katsutoshi Naruse; Hiroshi Nagashima; Yasuyuki Sakai; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

Review 5.  Artificial liver support at present and in the future.

Authors:  Kazuhiko Onodera; Hiromi Sakata; Motoki Yonekawa; Akio Kawamura
Journal:  J Artif Organs       Date:  2006       Impact factor: 1.731

6.  Interferon and cyclosporin A in the treatment of fulminant viral hepatitis.

Authors:  M Yoshiba; K Sekiyama; K Inoue; R Fujita
Journal:  J Gastroenterol       Date:  1995-02       Impact factor: 7.527

7.  Prognostic value of hepatic volumetry in fulminant hepatic failure.

Authors:  K Sekiyama; M Yoshiba; K Inoue; F Sugata
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

Review 8.  Artificial liver. State of the art.

Authors:  T Takahashi; P S Malchesky; Y Nosé
Journal:  Dig Dis Sci       Date:  1991-09       Impact factor: 3.199

9.  Development of reliable artificial liver support (ALS)--plasma exchange in combination with hemodiafiltration using high-performance membranes.

Authors:  M Yoshiba; K Sekiyama; Y Iwamura; F Sugata
Journal:  Dig Dis Sci       Date:  1993-03       Impact factor: 3.199

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.